Ambros Therapeutics Inc

📅 Upcoming

🕒 Recent(90d)

News

• This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
  RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmar…
  biopharma_dive · 22d ago
• A booming business on Wall Street would love more biotechs to quietly die
  Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.
  biopharma_dive · 23d ago
• FDA extends review of Capricor cell therapy; Pain drug startup to go public
  The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
  biopharma_dive · 1mo ago
• Chronic pain biotech co-founded by Vivek Ramaswamy joins reverse merger train
  A California biotech with a chronic pain drug that's long been approved in Italy, but not the US, is going onto the public markets through the increasingly popular reverse merger route. Ambros ...
  endpoints · 1mo ago
• Werewolf and Ambros to tie the knot in $150M rare disease deal
  The merger, which would create a new company bearing Ambros’ name, will help support development of Ambros' non-opioid painkiller for patients with debilitating limb injuries.
  biospace · 1mo ago
• Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug
  Werewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and has raised $150 million, positioning the biotech to…
  fiercebiotech · 1mo ago